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Body Fat Distribution and
Incident Cardiovascular
Disease in Obese AdultsEmerging evidence suggests that signiﬁcant hetero-
geneity exists in the cardiometabolic risk associated
with excess body fat in obese individuals (1). We
investigated the associations of novel imaging
markers of adiposity, including visceral adipose tis-
sue (VAT) and abdominal subcutaneous adipose tis-
sue (SAT) by magnetic resonance imaging, lower body
subcutaneous adipose tissue (LBAT) by dual-energy
x-ray absorptiometry, and liver fat by magnetic
resonance spectroscopy, with the risk for cardiovas-
cular disease (CVD) events in a multiethnic cohort of
obese adults.
The Dallas Heart Study is a cohort study with
methods previously described (1). Participants with
body mass index (BMI) values <30 kg/m2, prevalent
CVD, and missing imaging data were excluded. The
primary outcome was a composite of a ﬁrst or sub-
sequent CVD event: cardiovascular death; myocardial
infarction, hospitalized unstable angina, or coronary
revascularization; ischemic stroke, transient ischemic
attack, or cerebrovascular revascularization; periph-
eral arterial revascularization; hospitalization for
heart failure; or hospitalization for atrial ﬁbrillation.FIGURE 1 Associations of Imaging-Based Markers of Adipose Tissue
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Cumulative incidence of cardiovascular disease (CVD) by visceral (A) andMultivariate-adjusted marginal Cox proportional
hazards modeling using the Wei-Lin-Weissfeld
method for recurrent events (2) was used to calcu-
late hazard ratios and 95% conﬁdence intervals for
the primary outcome associated with baseline mea-
surements of each adiposity marker.
A total of 972 obese participants (mean age 44
years, 62% women, 54% African-Americans) were
followed for a median of 9.1 years. Eighty-one in-
dividuals had ﬁrst or subsequent CVD events,
resulting in 108 events. The cumulative incidence of
CVD increased in a stepwise fashion across sex- and
race-speciﬁc quartiles of VAT, from 5.3% in quartile 1
to 10.0% in quartile 4 (Figure 1A). In contrast, an
opposite association was observed for LBAT: the CVD
event rate was 10.0% in quartile 1 and 5.4% in quartile
4 (Figure 1B). BMI, abdominal SAT, and liver fat were
not associated with CVD. In multivariate analyses
adjusting for age, sex, race, hypercholesterolemia,
smoking status, and BMI, VAT remained associated
with CVD (hazard ratio per 1 SD: 1.21; 95% conﬁdence
interval: 1.03 to 1.43), whereas LBAT was inversely
associated with CVD (hazard ratio per 1 SD: 0.56; 95%
CI: 0.44 to 0.72). Adjustment for hypertension, bio-
markers of inﬂammation, insulin resistance, and
dyslipidemia, and for adipocytokines, did not atten-
uate these associations. Adjustment for baseline dia-
betes status modestly attenuated the association of
VAT with CVD. Lean mass and physical activity both
were inversely associated with CVD and mildly
attenuated the relation between VAT and CVD. Sub-
stitution of waist circumference for BMI showed
generally consistent results; there was no indepen-
dent association of waist circumference with theDistribution With CVD Events
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2151development of CVD. No statistically signiﬁcant in-
teractions by sex or race were found on the relation-
ship between VAT or LBAT and CVD in fully adjusted
models.
Here we report substantial heterogeneity in the
cardiovascular phenotype of obesity, with increased
risk observed with VAT and decreased risk with LBAT.
In contrast, BMI, abdominal SAT, and liver fat were
not signiﬁcantly associated with CVD. Our ﬁndings
suggest that the biological link between fat distribu-
tion and CVD may be at least partly independent of
traditional CVD risk factors and the inﬂuence of
inﬂammation and adipocytokines but that diabetes
may have a role in the etiological pathway between
VAT and CVD. Findings with lean mass and physical
activity are consistent with data that increasing
muscle mass and physical activity may counteract the
negative effects of VAT through fatty acid catabolism
and prevention of insulin resistance (3). The mecha-
nism behind the protective effect of LBAT may relate
to its ability to act as a metabolic sink, buffering the
inﬂux of dietary lipids and protecting other tissues,
including the heart, from lipotoxicity caused by lipid
overﬂow and ectopic fat deposition (4).
Although we focus primarily on the divergent
biology of different adipose depots in the devel-
opment of CVD, our ﬁndings also suggest that ad-
vanced imaging tools may provide a more accurate
phenotypic characterization of obesity than standard
anthropometric measurements, allowing better dis-
crimination of CVD risk. They also suggest that
therapies aimed at redistribution of fat away from
the visceral depot toward the more favorable lower
body subcutaneous depot may be more effective for
preventing cardiovascular complications in obesity
than simply targeting body mass reduction. Whether
modiﬁed diet, exercise, pharmacologic agents, or
bariatric surgery can promote this favorable redistri-
bution of body fat has yet to be determined. Larger
studies are needed to determine if adipose depot–
speciﬁc measurement can improve risk assessment
or serve as a treatment target in obese patients.*Ian J. Neeland, MD
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Copper, Coronary
Heart Disease, and
DehydroepiandrosteroneTivesten et al. (1) measured dehydroepiandrosterone
(DHEA) in serum of nearly 2,500 Swedish men aged
69 to 81 years. Low serum levels of DHEA and its
sulfate predicted increased risk of coronary heart
disease death after 5 years. They reviewed more than
a dozen earlier articles, mentioned that some people
use DHEA as a dietary supplement, and made a plea
for mechanistic studies.
Adult rats have concentrations of DHEA similar to
those in their Table 2. These can be halved by copper
deﬁciency because copper enzymes generally are
oxidative and DHEA is synthesized from cholesterol
by oxidation (2).
The Western diet often is low in copper, and cop-
per values in dietary surveys are falsely high (3).
Copper deﬁciency is the only nutritional insult that
elevates cholesterol, blood pressure, homocysteine,
isoprostanes, and uric acid; has adverse effects
on arteries and electrocardiograms; impairs glucose
tolerance and paraoxonase activity; promotes
thrombosis and oxidative damage; and to which
